TABLE 2.

Health Care Perspective

Treatment	Comparator	Incremental cost-effectiveness ratios
		Cost per QALYb	Cost per evLYGb
Abrocitiniba	Standard of care	$148,300	$148,300
Baricitinib		$71,600	$71,600
Tralokinumaba		$129,400	$129,400
Upadacitinib		$248,400	$248,400
Dupilumab		$110,300	$110,300
Abrocitiniba	Dupilumab	$303,400	$303,400
Baricitinib		Less costly, less effective	Less costly, less effective
Tralokinumaba		Less costly, less effective	Less costly, less effective
Upadacitinib		$1,912,200	$1,912,200

^a Using placeholder price.

^b The cost per QALY and cost per evLYG ratios were the same, given that the treatments have not been shown to lengthen life.

evLYG = equal value life-year gained; QALY = quality-adjusted life-year.